FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033706053> ?p ?o ?g. }

• W3033706053 endingPage "106385" @default.
• W3033706053 startingPage "106385" @default.
• W3033706053 abstract "There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation and -expansion study (NCT02588092) assessed the safety, activity, pharmacokinetics (PK), and immunogenicity of camidanlumab tesirine in patients with relapsed/refractory ALL/AML. A total of 35 patients (34 AML and 1 ALL) were enrolled and received camidanlumab tesirine intravenously at 3–92 μg/kg once every three weeks (Q3W, n = 26) or 30 or 37.5 μg/kg every week (QW, n = 9). One dose-limiting toxicity of maculopapular rash occurred in the 30 μg/kg QW group; the maximum tolerated dose was not reached. No additional safety concerns or adverse events (AEs) of interest were identified. The most common (>10 % of patients) Grade ≥3 treatment-emergent AEs were febrile neutropenia (25.7 %), lymphopenia, neutropenia, thrombocytopenia or fatigue (all 14.3 %), pneumonia, increased gamma-glutamyltransferase, and hypophosphatemia (each 11.4 %). No signal for serious immune-related AEs such as Guillain-Barré syndrome/polyradiculopathy was observed and there was no evidence of immunogenicity. PK showed rapid clearance with apparent half-life <2 days for conjugated and total antibody, suggesting that Q3W dosing may be insufficient for therapeutic efficacy, and prompting exploration of a QW schedule. Two patients achieved complete responses with incomplete hematologic recovery; one each at 30 and 37.5 μg/kg QW. The trial was terminated during dose escalation due to programmatic reasons other than safety. Hence, recommended dose was not determined." @default.
• W3033706053 created "2020-06-12" @default.
• W3033706053 creator A5001124933 @default.
• W3033706053 creator A5004066032 @default.
• W3033706053 creator A5005939966 @default.
• W3033706053 creator A5010569127 @default.
• W3033706053 creator A5013626352 @default.
• W3033706053 creator A5017509777 @default.
• W3033706053 creator A5019666497 @default.
• W3033706053 creator A5030259050 @default.
• W3033706053 creator A5031182692 @default.
• W3033706053 creator A5044613951 @default.
• W3033706053 creator A5059283771 @default.
• W3033706053 creator A5061865992 @default.
• W3033706053 creator A5066260049 @default.
• W3033706053 creator A5068778166 @default.
• W3033706053 creator A5074297763 @default.
• W3033706053 date "2020-08-01" @default.
• W3033706053 modified "2023-10-06" @default.
• W3033706053 title "Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study" @default.
• W3033706053 cites W1879221139 @default.
• W3033706053 cites W1988623079 @default.
• W3033706053 cites W1990483045 @default.
• W3033706053 cites W1991286650 @default.
• W3033706053 cites W1996773578 @default.
• W3033706053 cites W2003424912 @default.
• W3033706053 cites W2006732787 @default.
• W3033706053 cites W2007433984 @default.
• W3033706053 cites W2031091007 @default.
• W3033706053 cites W2032111684 @default.
• W3033706053 cites W2049770720 @default.
• W3033706053 cites W2068796184 @default.
• W3033706053 cites W2069160383 @default.
• W3033706053 cites W2084878791 @default.
• W3033706053 cites W2094546718 @default.
• W3033706053 cites W2116858301 @default.
• W3033706053 cites W2121080857 @default.
• W3033706053 cites W2141199885 @default.
• W3033706053 cites W2149711103 @default.
• W3033706053 cites W2159507916 @default.
• W3033706053 cites W2513682949 @default.
• W3033706053 cites W2607137647 @default.
• W3033706053 cites W2612193865 @default.
• W3033706053 cites W2618202329 @default.
• W3033706053 cites W2729933791 @default.
• W3033706053 cites W2774586064 @default.
• W3033706053 cites W2781864644 @default.
• W3033706053 cites W2797695105 @default.
• W3033706053 cites W2800550514 @default.
• W3033706053 cites W2839071055 @default.
• W3033706053 cites W2888048770 @default.
• W3033706053 cites W2893003701 @default.
• W3033706053 cites W2909300449 @default.
• W3033706053 cites W2911285649 @default.
• W3033706053 cites W2912558146 @default.
• W3033706053 cites W2915597716 @default.
• W3033706053 cites W2923660448 @default.
• W3033706053 cites W2931981435 @default.
• W3033706053 cites W4376595466 @default.
• W3033706053 doi "https://doi.org/10.1016/j.leukres.2020.106385" @default.
• W3033706053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32521310" @default.
• W3033706053 hasPublicationYear "2020" @default.
• W3033706053 type Work @default.
• W3033706053 sameAs 3033706053 @default.
• W3033706053 citedByCount "24" @default.
• W3033706053 countsByYear W30337060532020 @default.
• W3033706053 countsByYear W30337060532021 @default.
• W3033706053 countsByYear W30337060532022 @default.
• W3033706053 countsByYear W30337060532023 @default.
• W3033706053 crossrefType "journal-article" @default.
• W3033706053 hasAuthorship W3033706053A5001124933 @default.
• W3033706053 hasAuthorship W3033706053A5004066032 @default.
• W3033706053 hasAuthorship W3033706053A5005939966 @default.
• W3033706053 hasAuthorship W3033706053A5010569127 @default.
• W3033706053 hasAuthorship W3033706053A5013626352 @default.
• W3033706053 hasAuthorship W3033706053A5017509777 @default.
• W3033706053 hasAuthorship W3033706053A5019666497 @default.
• W3033706053 hasAuthorship W3033706053A5030259050 @default.
• W3033706053 hasAuthorship W3033706053A5031182692 @default.
• W3033706053 hasAuthorship W3033706053A5044613951 @default.
• W3033706053 hasAuthorship W3033706053A5059283771 @default.
• W3033706053 hasAuthorship W3033706053A5061865992 @default.
• W3033706053 hasAuthorship W3033706053A5066260049 @default.
• W3033706053 hasAuthorship W3033706053A5068778166 @default.
• W3033706053 hasAuthorship W3033706053A5074297763 @default.
• W3033706053 hasConcept C121332964 @default.
• W3033706053 hasConcept C126322002 @default.
• W3033706053 hasConcept C142424586 @default.
• W3033706053 hasConcept C203014093 @default.
• W3033706053 hasConcept C2776694085 @default.
• W3033706053 hasConcept C2776863199 @default.
• W3033706053 hasConcept C2777063308 @default.
• W3033706053 hasConcept C2778168870 @default.
• W3033706053 hasConcept C2778461978 @default.
• W3033706053 hasConcept C2778570526 @default.
• W3033706053 hasConcept C2778729363 @default.
• W3033706053 hasConcept C2779788671 @default.
• W3033706053 hasConcept C29730261 @default.

• next